We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+4.23%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.4B
AUM Growth
+$2.4B
Cap. Flow
+$169M
Cap. Flow %
7.05%
Top 10 Hldgs %
44.25%
Holding
367
New
126
Increased
77
Reduced
66
Closed
85

Top Buys

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$94.4M
2
IWM icon
iShares Russell 2000 ETF
IWM
+$24M
3
AGN
Allergan plc
AGN
+$13.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$11.9M
5
MBLY
Mobileye N.V.
MBLY
+$8.8M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$42.1M
2
GILD icon
Gilead Sciences
GILD
+$11.5M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$11.1M
4
A icon
Agilent Technologies
A
+$6.68M
5
ADVM
Adverum Biotechnologies
ADVM
+$3.71M

Sector Composition

Rank Sector Weight
1 Healthcare 9.36%
2 Technology 0.55%
3 Energy 0.39%
4 Industrials 0.16%
5 Financials 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRDC
126
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$2.43M 0.1%
386,372
+71,706
+23% +$441K
ITCI
127
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.39M 0.1%
+100,000
New +$2.24M
ACHC icon
128
PUT
Acadia Healthcare
ACHC
$3.01B
$2.37M 0.1%
+728
New +$46.7K
ENDP
129
DELISTED
Endo International plc
ENDP
$2.33M 0.1%
+25,991
New +$2.17M
APEN
130
DELISTED
Apollo Endosurgery, Inc.
APEN
$2.32M 0.1%
12,204
-4,005
-25% -$920K
AGIO icon
131
CALL
Agios Pharmaceuticals
AGIO
$2.14B
$2.29M 0.1%
+243
New +$27.2K
A icon
132
PUT
Agilent Technologies
A
$39.7B
$2.24M 0.09%
540
+369
+216% +$14.9K
ADVM
133
DELISTED
Adverum Biotechnologies
ADVM
$2.23M 0.09%
5,494
-8,786
-62% -$3.71M
RMTI icon
134
CALL
Rockwell Medical
RMTI
$27.6M
$2.19M 0.09%
18
-19
-51% -$22.3K
SCON
135
DELISTED
Superconductor Technologies Inc.
SCON
$2.14M 0.09%
+1,011
New +$3.36M
PBYI icon
136
Puma Biotechnology
PBYI
$406M
$2.13M 0.09%
9,044
-9,816
-52% -$2.1M
TXMD icon
137
CALL
TherapeuticsMD
TXMD
$23.8M
$2.11M 0.09%
70
+66
+1,650% +$16.1K
EPZM
138
DELISTED
Epizyme, Inc
EPZM
$2.1M 0.09%
+111,536
New +$2.3M
MDCO
139
PUT
DELISTED
Medicines Co
MDCO
$2.07M 0.09%
738
+576
+356% +$16.2K
ARWR icon
140
CALL
Arrowhead Research
ARWR
$12.1B
$2.06M 0.09%
+3,053
New +$21.7K
CLRB icon
141
Cellectar Biosciences
CLRB
$20M
$2.02M 0.08%
22
+1
+5% +$80.3K
PGNX
142
PUT
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$2.01M 0.08%
+3,359
New +$21.1K
PBYI icon
143
CALL
Puma Biotechnology
PBYI
$406M
$1.96M 0.08%
+83
New +$17.7K
FOLD
144
CALL
DELISTED
Amicus Therapeutics
FOLD
$1.94M 0.08%
1,784
+1,238
+227% +$10.9K
TRUP icon
145
Trupanion
TRUP
$1.11B
$1.92M 0.08%
240,000
-105,205
-30% -$799K
VNDA icon
146
CALL
Vanda Pharmaceuticals
VNDA
$310M
$1.88M 0.08%
2,019
+1,519
+304% +$17.2K
SGYPW
147
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
$1.87M 0.08%
404,627
-56,118
-12% -$46K
ICPT
148
PUT
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.86M 0.08%
+66
New +$14.3K
INCY icon
149
CALL
Incyte
INCY
$26B
$1.84M 0.08%
+201
New +$16.6K
TTHI
150
DELISTED
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
$1.83M 0.08%
+268,400
New +$1.85M
4 5
6
7 8

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2015 Portfolio in Review

As of Q1 2015, Sabby Management held 367 positions worth $2.4B, up 75,773% from $3.17M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management deployed $169M of net new capital in Q1 2015, opening 126 new positions and adding to 77 existing holdings. Its largest new stake was Tempest Therapeutics: 709 shares worth $4.69M.

By sector, the portfolio is most concentrated in Healthcare at 9.4% of assets, up from 9.2% a quarter earlier, followed by Technology and Energy.

On the sell side, the largest reduction was Achillion Pharmaceuticals, an estimated $11.1M trimmed.

  • Sabby Management's largest Q1 2015 buy was Tempest Therapeutics: 709 shares worth $4.69M.
  • Sabby Management added most to Allergan plc in Q1 2015, an estimated $13.8M increase.
  • Sabby Management's biggest Q1 2015 reduction was Achillion Pharmaceuticals, cutting an estimated $11.1M.
  • Sabby Management fully exited Pfizer in Q1 2015, selling an estimated $42.1M.
  • Sabby Management's ten largest holdings make up 44% of its $2.4B portfolio in Q1 2015.
  • Sabby Management opened 126 new positions and closed 85 in Q1 2015.
  • Sabby Management's portfolio value rose 75,773% quarter-over-quarter to $2.4B.

Based on Sabby Management's 13F filing for Q1 2015, filed 15 May 2015.